{"id":39745,"date":"2020-07-01T21:47:11","date_gmt":"2020-07-02T04:47:11","guid":{"rendered":"https:\/\/cjnotebook.com\/?p=39745"},"modified":"2020-07-01T21:47:11","modified_gmt":"2020-07-02T04:47:11","slug":"pharmaceutical-corp-pay-642-million-to-settle-allegations-of-improper-payments-to-patients-doctors","status":"publish","type":"post","link":"https:\/\/cjnotebook.com\/?p=39745","title":{"rendered":"Pharmaceutical Corp. Pay $642 Million to Settle Allegations of Improper Payments to Patients, Doctors"},"content":{"rendered":"<div class=\"field field--name-field-pr-body field--type-text-long field--label-hidden\">\n<div class=\"field__items\">\n<div class=\"field__item even\">\n<p>&nbsp;<\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed\u00a0 to pay over $642 million in separate settlements claims that it violated federal laws,\u00a0 officials announced Wednesday.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The first settlement pertains to the company\u2019s alleged illegal use of three foundations as conduits to pay the copayments of Medicare patients taking Novartis\u2019s drugs Gilenya and Afinitor.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The second settlement resolves claims arising from the company\u2019s alleged payments of kickbacks to doctors.<\/span><\/p>\n<figure id=\"attachment_2058\" aria-describedby=\"caption-attachment-2058\" style=\"width: 300px\" class=\"wp-caption alignleft\"><a href=\"https:\/\/cjnotebook.com\/l-physician-assistant-plead-guilty-medicare-fraud\/medicare\/\" rel=\"attachment wp-att-2058\"><img loading=\"lazy\" decoding=\"async\" class=\"size-medium wp-image-2058\" src=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/03\/Medicare-300x270.jpg\" alt=\"\" width=\"300\" height=\"270\" srcset=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/03\/Medicare-300x270.jpg 300w, https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/03\/Medicare.jpg 320w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><figcaption id=\"caption-attachment-2058\" class=\"wp-caption-text\">Medicare<\/figcaption><\/figure>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">\u201cThrough this settlement and others, the government has demonstrated its commitment to ensuring that drug companies do not use kickbacks to influence the drugs prescribed by doctors or purchased by patients,\u201d said Assistant Attorney General Jody Hunt of the Department of Justice\u2019s Civil Division.\u00a0 \u201cWe will continue to safeguard the Medicare program from kickbacks and their pernicious effects, including the undermining of important cost-control mechanisms instituted by Congress.\u201d<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The Anti-Kickback Statute prohibits anyone from offering or paying, directly or indirectly, any remuneration \u2014 which includes money or any other thing of value \u2014 to induce referrals of items or services covered by Medicare, Medicaid, and other federally funded programs. \u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">This prohibition extends not only to improper payments to providers, but also to the improper payment of patients\u2019 copay obligations.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">In the first settlement, Novartis has agreed to pay $51.25 million to resolve allegations that it illegally paid the copay obligations for patients taking its drugs.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\"><a href=\"https:\/\/cjnotebook.com\/philadelphia-woman-convicted-firebombing-killed-people\/criminal_justice_jurisprudence-2\/\" rel=\"attachment wp-att-1073\"><img loading=\"lazy\" decoding=\"async\" class=\"size-full wp-image-1073 alignright\" src=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/02\/criminal_justice_jurisprudence-2.jpg\" alt=\"\" width=\"299\" height=\"188\" srcset=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/02\/criminal_justice_jurisprudence-2.jpg 299w, https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/02\/criminal_justice_jurisprudence-2-120x76.jpg 120w, https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/02\/criminal_justice_jurisprudence-2-265x168.jpg 265w, https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/02\/criminal_justice_jurisprudence-2-284x180.jpg 284w, https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/02\/criminal_justice_jurisprudence-2-274x173.jpg 274w\" sizes=\"auto, (max-width: 299px) 100vw, 299px\" \/><\/a>When a Medicare beneficiary obtains a prescription drug covered by Medicare, the beneficiary may be required to make a partial payment, which may take the form of a copayment, coinsurance, or a deductible (collectively \u201ccopays\u201d).\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Congress included copay requirements in the Medicare program, in part, to serve as a check on health care costs, including the prices that pharmaceutical manufacturers can demand for their drugs.\u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Novartis sells Gilenya, which is approved for treatment of relapsing forms of multiple sclerosis (MS).\u00a0 \u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The government alleged that, in October 2012, Novartis learned from the contractor managing Novartis\u2019s free drug program for Gilenya that over 300 patients who were receiving free drugs would be eligible for Medicare in 2013.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Novartis and the contractor transitioned those patients to Medicare Part D so that, in the future, Novartis would obtain revenue from Medicare when those patients filled prescriptions for Gilenya.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Knowing those patients could not afford the copay for Gilenya, Novartis developed a plan with a foundation so that Novartis could cover the copays for those patients.\u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\"> <a href=\"https:\/\/cjnotebook.com\/englishman-sentenced-16-years-traveling-ohio-sex-minor\/u-s-justice-dept\/\" rel=\"attachment wp-att-1499\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-1499 alignleft\" src=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/03\/U.S.-Justice-Dept-e1394578665196-300x170.jpg\" alt=\"\" width=\"498\" height=\"282\" srcset=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/03\/U.S.-Justice-Dept-e1394578665196-300x170.jpg 300w, https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/03\/U.S.-Justice-Dept-e1394578665196.jpg 417w\" sizes=\"auto, (max-width: 498px) 100vw, 498px\" \/><\/a>Specifically, at the same time Novartis made a payment to the foundation, Novartis arranged for the foundation to open its MS fund at 6:00 pm on a Friday and for the contractor to have personnel working overtime to submit applications for those patients who had been receiving free Gilenya.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Novartis knew that this coordination would result in a disproportionate share of its funding going to Gilenya patients for 2013.\u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Novartis also sells Afinitor, which is a second-line treatment for advanced renal cell carcinoma (RCC) and treatment for progressive neuroendocrine tumors of pancreatic origin (PNET).\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The government alleged that Novartis learned that, for the 2010 donation year, it would be the only donor to an RCC copay assistance fund operated by a charitable foundation.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The government alleged that Novartis told the foundation that it would be willing to donate to the fund only if the eligibility definition was narrowed in a way that ensured that a greater amount of the copay assistance would support patients taking Afinitor.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The government alleged that, as a result of narrowing the fund definition, the fund disproportionately assisted patients taking Afinitor compared to its overall usage rate among RCC drugs.<\/span><\/p>\n<p><a href=\"https:\/\/cjnotebook.com\/sexual-harassment\/justice-scales\/\" rel=\"attachment wp-att-4817\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-4817  alignright\" src=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/07\/Justice-Scales-300x102.jpg\" alt=\"\" width=\"574\" height=\"197\" srcset=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/07\/Justice-Scales-300x102.jpg 300w, https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/07\/Justice-Scales.jpg 675w\" sizes=\"auto, (max-width: 574px) 100vw, 574px\" \/><\/a><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The government further alleged that, in 2012, Novartis asked another foundation to open a copay assistance fund to pay copays for PNET patients, which Novartis knew would be used only to pay the copays of Afinitor patients.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">\u201cAccording to the allegations in today\u2019s settlement, Novartis coordinated with three co-pay foundations to funnel money through the foundations to patients taking Novartis\u2019 own drugs,\u201d said U.S. Attorney Andrew E. Lelling for the District of Massachusetts.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Adding,\u201cAs a result, the Novartis\u2019 conduct was not \u2018charitable,\u2019 but rather functioned as a kickback scheme that undermined the structure of the Medicare program and illegally subsidized the high costs of Novartis\u2019s drugs at the expense of American taxpayers.\u00a0 At the same time, we recognize that Novartis\u2019 current management has taken constructive steps to address the government\u2019s concerns with the company\u2019s prior relationships with co-pay foundations.\u201d<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\"><a href=\"https:\/\/cjnotebook.com\/sheriffs-deputy-charged-with-shooting-an-unarmed-person-and-lying-about-it\/courtroom-federal-2\/\" rel=\"attachment wp-att-37893\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-37893 alignleft\" src=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2019\/08\/courtroom-federal.jpg\" alt=\"\" width=\"481\" height=\"276\" \/><\/a>In the second matter, Novartis will pay $591,442,008 to resolve FCA claims that it paid kickbacks to doctors to induce them to prescribe the Novartis drugs Lotrel, Valturna, Starlix, Tekturna, Tekturna HCT, Tekamlo, Diovan, Diovan HCT, Exforge, and Exforge HCT.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">In addition, Novartis will forfeit $38.4 million under the Civil Asset Forfeiture Statute.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Novartis also made extensive factual admissions in the settlement and agreed to strict limitations on any future speaker programs, including reductions to the amount it may spend on such programs.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">In a case pending in the Southern District of New York, the United States alleged that Novartis hosted tens of thousands of speaker programs and related events under the guise of providing educational content, when in fact the events served as nothing more than a means to provide bribes to doctors.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Novartis paid physicians honoraria, purportedly as compensation for delivering a lecture regarding a Novartis medication, but, as Novartis knew, many of these programs were nothing more than social events held at expensive restaurants, with little or no discussion about the Novartis drugs.\u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\"> Indeed, some of the so-called speaker events never even took place; the speaker was simply paid a fee in order to induce the speaker to prescribe Novartis drugs.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">\u201cFor more than a decade, Novartis spent hundreds of millions of dollars on so-called speaker programs, including speaking fees, exorbitant meals, and top-shelf alcohol that were nothing more than bribes to get doctors across the country to prescribe Novartis\u2019s drugs,\u201d said Acting U.S. Attorney Audrey Strauss for the Southern District of New York.\u00a0 \u201cGiving these cash payments and other lavish goodies interferes with the duty of doctors to choose the best treatment for their patients and increase drug costs for everyone.\u00a0 This office will continue to be vigilant in cracking down on kickbacks, however they may be dressed up, throughout the pharmaceutical industry.\u201d<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The government\u2019s complaint further alleged that Novartis sales representatives, on the instruction of their managers, selected high-volume prescribers to serve as the paid \u201cspeakers\u201d at these events with the intent to induce them to write more \u2014 or keep writing many \u2014 Novartis prescriptions.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The sales representatives then pressured the speakers to increase their prescriptions of Novartis drugs, and often dropped doctors from the speaker program if they failed to do so.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Further, the government alleged that this widespread kickback scheme was the result of decisions made by top management at Novartis\u2019s North American headquarters in New Jersey.\u00a0\u00a0\u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">This settlement resolves a lawsuit captioned\u00a0<em>United States ex rel. Bilotta v. Novartis Pharmaceuticals Corp.<\/em>, No. 11-Civ.-0071-PGG (S.D.N.Y.) initially filed under the whistleblower provision of the FCA, which permits private parties to file suit on behalf of the United States for false claims and share in a portion of the government\u2019s recovery.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The FCA permits the United States to intervene in such a lawsuit, as it did in the whistleblower case filed against Novartis.\u00a0 The amount to be recovered by the private whistleblower, Oswald Bilotta, has not yet been determined.\u00a0 As part of the settlement, Novartis will also pay an additional $48,151,273 to resolve state Medicaid claims.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Contemporaneous with the settlement of the FCA claims in these matters, Novartis entered into a corporate integrity agreement (CIA) with the Department of Health and Human Services Office of Inspector General (HHS-OIG).\u00a0 The five-year CIA addresses the conduct at issue in both matters.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Among other things, the CIA requires Novartis to significantly reduce the number of paid speaker programs and the amounts spent on such programs.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Under the CIA, Novartis speaker programs may only occur under limited circumstances and in a virtual format.\u00a0 In addition, the CIA requires Novartis to implement measures designed to promote independence from any patient assistance programs to which it contributes.\u00a0 <\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The CIA also requires multi-faceted monitoring of Novartis\u2019s operations and obligates company executives and Board members to certify about compliance.<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">\u201cOIG will continue to work closely with the Department of Justice to investigate and pursue kickbacks regardless of the form they take,\u201d said Gregory E. Demske, Chief Counsel to the Inspector General, HHS-OIG.\u00a0 \u201cTo address Novartis\u2019s conduct and the widely-recognized compliance risks associated with paid speaker programs, the CIA requires Novartis to make fundamental changes to its speaker program practices.\u00a0 Under the CIA, Novartis must significantly reduce the number of programs and the number of paid physicians, and can no longer pay for inherently-risky in-person programs.\u201d\u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">The government\u2019s resolution of these matters illustrates the government\u2019s emphasis on combating healthcare fraud. \u00a0One of the most powerful tools in this effort is the False Claims Act. \u00a0<\/span><\/p>\n<p style=\"text-align: center;\"><span style=\"font-size: 18pt;\">Tips and complaints from all sources about potential fraud, waste, abuse, and mismanagement, can be reported to the Department of Health and Human Services at 800-HHS-TIPS (800-447-8477).<\/span><\/p>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed\u00a0 to pay over $642 million in separate settlements claims that it violated federal laws,\u00a0 officials announced Wednesday&#8230;.<\/p>\n","protected":false},"author":1,"featured_media":39748,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3258],"tags":[],"class_list":["post-39745","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-courts-cases"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pharmaceutical Corp. Pay $642 Million to Settle Allegations of Improper Payments to Patients, Doctors<\/title>\n<meta name=\"description\" content=\"&nbsp; Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed\u00a0 to pay over $642 million in\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cjnotebook.com\/?p=39745\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pharmaceutical Corp. Pay $642 Million to Settle Allegations of Improper Payments to Patients, Doctors\" \/>\n<meta property=\"og:description\" content=\"&nbsp; Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed\u00a0 to pay over $642 million in\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cjnotebook.com\/?p=39745\" \/>\n<meta property=\"og:site_name\" content=\"American Justice Notebook\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/AmericanJusticeNotebook\" \/>\n<meta property=\"article:published_time\" content=\"2020-07-02T04:47:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cjnotebook.com\/wp-content\/uploads\/2020\/07\/Screen-Shot-2017-05-23-at-12.05.12-PM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"752\" \/>\n\t<meta property=\"og:image:height\" content=\"486\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Raul\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Raul\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=39745#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=39745\"},\"author\":{\"name\":\"Raul\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#\\\/schema\\\/person\\\/f5521baddca77b521f012298775186c0\"},\"headline\":\"Pharmaceutical Corp. Pay $642 Million to Settle Allegations of Improper Payments to Patients, Doctors\",\"datePublished\":\"2020-07-02T04:47:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=39745\"},\"wordCount\":1543,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=39745#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/Screen-Shot-2017-05-23-at-12.05.12-PM.png\",\"articleSection\":[\"Courts &amp; Cases\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/cjnotebook.com\\\/?p=39745#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=39745\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/?p=39745\",\"name\":\"Pharmaceutical Corp. Pay $642 Million to Settle Allegations of Improper Payments to Patients, Doctors\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=39745#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=39745#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/Screen-Shot-2017-05-23-at-12.05.12-PM.png\",\"datePublished\":\"2020-07-02T04:47:11+00:00\",\"description\":\"&nbsp; Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed\u00a0 to pay over $642 million in\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/cjnotebook.com\\\/?p=39745\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/?p=39745#primaryimage\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/Screen-Shot-2017-05-23-at-12.05.12-PM.png\",\"contentUrl\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2020\\\/07\\\/Screen-Shot-2017-05-23-at-12.05.12-PM.png\",\"width\":752,\"height\":486},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#website\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/\",\"name\":\"American Justice Notebook\",\"description\":\"&quot;Our liberty depends on the freedom of the press, and that cannot be limited without being lost.&quot; \u2014  Thomas Jefferson\",\"publisher\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/cjnotebook.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#organization\",\"name\":\"American Justice Notebook\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2014\\\/07\\\/Justice-Scales.jpg\",\"contentUrl\":\"https:\\\/\\\/cjnotebook.com\\\/wp-content\\\/uploads\\\/2014\\\/07\\\/Justice-Scales.jpg\",\"width\":675,\"height\":231,\"caption\":\"American Justice Notebook\"},\"image\":{\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/AmericanJusticeNotebook\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/cjnotebook.com\\\/#\\\/schema\\\/person\\\/f5521baddca77b521f012298775186c0\",\"name\":\"Raul\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g\",\"caption\":\"Raul\"},\"description\":\"Raul Hernandez is a former journalist. He has worked as a newspaper reporter for more than 30 years at the El Paso Herald-Post, El Paso Times, Press Enterprise in Riverside, California and the Ventura County Star in California. He was a court reporter for more than 20 years.\",\"sameAs\":[\"https:\\\/\\\/cjnotebook.com\\\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pharmaceutical Corp. Pay $642 Million to Settle Allegations of Improper Payments to Patients, Doctors","description":"&nbsp; Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed\u00a0 to pay over $642 million in","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cjnotebook.com\/?p=39745","og_locale":"en_US","og_type":"article","og_title":"Pharmaceutical Corp. Pay $642 Million to Settle Allegations of Improper Payments to Patients, Doctors","og_description":"&nbsp; Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed\u00a0 to pay over $642 million in","og_url":"https:\/\/cjnotebook.com\/?p=39745","og_site_name":"American Justice Notebook","article_publisher":"https:\/\/www.facebook.com\/AmericanJusticeNotebook","article_published_time":"2020-07-02T04:47:11+00:00","og_image":[{"width":752,"height":486,"url":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2020\/07\/Screen-Shot-2017-05-23-at-12.05.12-PM.png","type":"image\/png"}],"author":"Raul","twitter_misc":{"Written by":"Raul","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cjnotebook.com\/?p=39745#article","isPartOf":{"@id":"https:\/\/cjnotebook.com\/?p=39745"},"author":{"name":"Raul","@id":"https:\/\/cjnotebook.com\/#\/schema\/person\/f5521baddca77b521f012298775186c0"},"headline":"Pharmaceutical Corp. Pay $642 Million to Settle Allegations of Improper Payments to Patients, Doctors","datePublished":"2020-07-02T04:47:11+00:00","mainEntityOfPage":{"@id":"https:\/\/cjnotebook.com\/?p=39745"},"wordCount":1543,"commentCount":0,"publisher":{"@id":"https:\/\/cjnotebook.com\/#organization"},"image":{"@id":"https:\/\/cjnotebook.com\/?p=39745#primaryimage"},"thumbnailUrl":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2020\/07\/Screen-Shot-2017-05-23-at-12.05.12-PM.png","articleSection":["Courts &amp; Cases"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cjnotebook.com\/?p=39745#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cjnotebook.com\/?p=39745","url":"https:\/\/cjnotebook.com\/?p=39745","name":"Pharmaceutical Corp. Pay $642 Million to Settle Allegations of Improper Payments to Patients, Doctors","isPartOf":{"@id":"https:\/\/cjnotebook.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cjnotebook.com\/?p=39745#primaryimage"},"image":{"@id":"https:\/\/cjnotebook.com\/?p=39745#primaryimage"},"thumbnailUrl":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2020\/07\/Screen-Shot-2017-05-23-at-12.05.12-PM.png","datePublished":"2020-07-02T04:47:11+00:00","description":"&nbsp; Pharmaceutical company Novartis Pharmaceuticals Corporation (Novartis), based in East Hanover, New Jersey, has agreed\u00a0 to pay over $642 million in","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cjnotebook.com\/?p=39745"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cjnotebook.com\/?p=39745#primaryimage","url":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2020\/07\/Screen-Shot-2017-05-23-at-12.05.12-PM.png","contentUrl":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2020\/07\/Screen-Shot-2017-05-23-at-12.05.12-PM.png","width":752,"height":486},{"@type":"WebSite","@id":"https:\/\/cjnotebook.com\/#website","url":"https:\/\/cjnotebook.com\/","name":"American Justice Notebook","description":"&quot;Our liberty depends on the freedom of the press, and that cannot be limited without being lost.&quot; \u2014  Thomas Jefferson","publisher":{"@id":"https:\/\/cjnotebook.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cjnotebook.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cjnotebook.com\/#organization","name":"American Justice Notebook","url":"https:\/\/cjnotebook.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cjnotebook.com\/#\/schema\/logo\/image\/","url":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/07\/Justice-Scales.jpg","contentUrl":"https:\/\/cjnotebook.com\/wp-content\/uploads\/2014\/07\/Justice-Scales.jpg","width":675,"height":231,"caption":"American Justice Notebook"},"image":{"@id":"https:\/\/cjnotebook.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/AmericanJusticeNotebook"]},{"@type":"Person","@id":"https:\/\/cjnotebook.com\/#\/schema\/person\/f5521baddca77b521f012298775186c0","name":"Raul","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c7f80bd073aca2abc2fc18e390e13d00b72d9d3a81bca4fd53e3567b02efee6f?s=96&r=g","caption":"Raul"},"description":"Raul Hernandez is a former journalist. He has worked as a newspaper reporter for more than 30 years at the El Paso Herald-Post, El Paso Times, Press Enterprise in Riverside, California and the Ventura County Star in California. He was a court reporter for more than 20 years.","sameAs":["https:\/\/cjnotebook.com\/"]}]}},"_links":{"self":[{"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/posts\/39745","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=39745"}],"version-history":[{"count":3,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/posts\/39745\/revisions"}],"predecessor-version":[{"id":39749,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/posts\/39745\/revisions\/39749"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=\/wp\/v2\/media\/39748"}],"wp:attachment":[{"href":"https:\/\/cjnotebook.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=39745"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=39745"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cjnotebook.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=39745"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}